Vaxcyte Inc (PCVX) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-1.35x
Vaxcyte Inc (PCVX) has a Cash Flow-to-Debt Ratio of -1.35x as of June 2026, meaning its operating cash flow of $-513.10 Million could theoretically repay -1% of its total liabilities ($380.21 Million) in one year. See PCVX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.35x
Operating CF / Total Liabilities
Operating Cash Flow
$-513.10 Million
USD
Total Liabilities
$380.21 Million
USD
Data as of
Jun 2026
Most recent filing
Vaxcyte Inc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Vaxcyte Inc across 9 annual periods. For the full cash flow conversion analysis, see Vaxcyte Inc operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Vaxcyte Inc (2017–2025)
Year-by-year debt coverage analysis for Vaxcyte Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.82x | $-655.58 Million | $360.45 Million | ▲ +17.4% |
| 2024 | -2.20x | $-452.63 Million | $205.50 Million | ▼ -24.3% |
| 2023 | -1.77x | $-296.79 Million | $167.45 Million | ▲ +45.4% |
| 2022 | -3.25x | $-170.60 Million | $52.56 Million | ▼ -7.8% |
| 2021 | -3.01x | $-121.39 Million | $40.32 Million | ▼ -203.4% |
| 2020 | -0.99x | $-46.63 Million | $46.98 Million | ▼ -262.2% |
| 2019 | -0.27x | $-47.15 Million | $172.07 Million | ▼ -15.6% |
| 2018 | -0.24x | $-30.47 Million | $128.53 Million | ▼ -13670.9% |
| 2017 | 0.00x | $-14.96K | $8.69 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.